MSB0010841

· Merck KGaA

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MSB0010841, covering 2017-01-19 to 2017-01-19. Get the full timeline:

Most recent: Clinical Trial Update: Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects [Phase 1]